Price Chart

Executive Summary

Insmed reported positive 12-month data from the ongoing open-label extension (OLE) study of TPIP (treprostinil palmitil inhalation powder) in pulmonary arterial hypertension (PAH). The data showed sustained improvements in exercise capacity (6MWD +55.7m for continued TPIP, +54.1m for placebo-crossed), NT-proBNP reduction (~60%), WHO Functional Class, and REVEAL Lite 2.0 mortality risk score, with no new safety signals. These results support the ongoing Phase 3 PALM-PAH trial and strengthen TPIP's profile as a potential best-in-class once-daily inhaled prostanoid.

Key Facts

• 12-month OLE data: mean 6MWD improvement of +55.7 meters (TPIP Continued) and +54.1 meters (Placebo Crossed) from baseline
• NT-proBNP reduced ~60% in both groups (geometric mean ratio 0.40 and 0.41)
• ~80% of patients achieved WHO Functional Class I or II; >25% achieved Class I
• Mean REVEAL Lite 2.0 score improved 2.0 points (Continued) and 1.4 points (Crossed); ~65% of all patients achieved Refined Low Risk status
• 91% patient completion rate at Month 12; no new safety signals; 4 deaths none considered drug-related
• TPIP is an investigational once-daily inhaled prostanoid; Phase 3 PALM-PAH trial is actively enrolling

Financial Impact

No financial data reported; clinical catalyst de-risks TPIP program and supports Phase 3 advancement

Risk Factors

• OLE study is open-label, single-arm, and non-placebo-controlled; results may not replicate in the Phase 3 randomized trial
• TPIP is investigational and not yet approved; regulatory approval is uncertain
• Competition from approved therapies (Tyvaso, Winrevair) and other pipeline candidates

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status